Stock DNA
Pharmaceuticals & Biotechnology
CNY 6,279 Million (Mid Cap)
12.00
NA
1.83%
-0.08
20.07%
2.42
Revenue and Profits:
Net Sales:
806 Million
(Quarterly Results - Jun 2025)
Net Profit:
166 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-11.24%
0%
-11.24%
6 Months
-2.54%
0%
-2.54%
1 Year
-37.99%
0%
-37.99%
2 Years
-32.61%
0%
-32.61%
3 Years
-34.19%
0%
-34.19%
4 Years
16.3%
0%
16.3%
5 Years
-31.74%
0%
-31.74%
Hunan Jiudian Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
28.18%
EBIT Growth (5y)
56.77%
EBIT to Interest (avg)
23.23
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.17
Sales to Capital Employed (avg)
1.07
Tax Ratio
10.02%
Dividend Payout Ratio
29.81%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
20.42%
ROE (avg)
18.06%
Valuation key factors
Factor
Value
P/E Ratio
12
Industry P/E
Price to Book Value
2.42
EV to EBIT
10.79
EV to EBITDA
9.04
EV to Capital Employed
2.55
EV to Sales
2.00
PEG Ratio
NA
Dividend Yield
1.83%
ROCE (Latest)
23.63%
ROE (Latest)
20.07%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
Bullish
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
806.30
766.40
5.21%
Operating Profit (PBDIT) excl Other Income
204.30
183.30
11.46%
Interest
3.30
5.20
-36.54%
Exceptional Items
0.00
0.00
Consolidate Net Profit
165.60
158.50
4.48%
Operating Profit Margin (Excl OI)
217.70%
209.80%
0.79%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 5.21% vs 8.52% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 4.48% vs 31.32% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
2,897.40
2,658.30
8.99%
Operating Profit (PBDIT) excl Other Income
637.50
441.60
44.36%
Interest
18.70
11.10
68.47%
Exceptional Items
0.00
0.00
Consolidate Net Profit
512.40
368.30
39.13%
Operating Profit Margin (Excl OI)
186.70%
138.90%
4.78%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 8.99% vs 15.60% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 39.13% vs 36.56% in Dec 2023
About Hunan Jiudian Pharmaceutical Co., Ltd. 
Hunan Jiudian Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






